Related Experiment Video

Updated: May 18, 2026

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

Notch3 overexpression as potential therapeutic target in advanced stage chemoresistant ovarian cancer

Mohammed Tanjimur Rahman1, Kentaro Nakayama, Munmun Rahman

  • 1Department of Obstetrics and Gynecology, Shimane University School of Medicine, Izumo, Japan.

American Journal of Clinical Pathology
|September 27, 2012
PubMed

Insights

Notch3 overexpression is linked to poorer survival and chemoresistance in advanced ovarian cancer. Inhibiting Notch3 shows promise as a new therapeutic strategy for treating this difficult-to-treat cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Ovarian cancer remains a leading cause of cancer-related death.
  • Chemoresistance significantly limits treatment efficacy in advanced ovarian cancer.
  • The role of Notch3 signaling in ovarian cancer progression and treatment resistance is not well understood.

Purpose of the Study:

  • To investigate the clinical significance of Notch3 expression in ovarian cancer.
  • To evaluate Notch3 as a potential therapeutic target in chemoresistant ovarian cancer.
  • To explore the functional role of Notch3 in ovarian cancer cell lines.

Main Methods:

  • Immunohistochemical examination of Notch3 expression in patient tumors.
  • Retrospective chart review of clinical variables.
  • In vitro studies using Notch3 siRNA and a gamma-secretase inhibitor in ovarian cancer cell lines.

Main Results:

  • Notch3 overexpression correlated with shorter progression-free and overall survival in advanced ovarian cancer patients treated with platinum and taxane.
  • Increased Notch3 immunostaining was observed in recurrent tumors compared to primary tumors in a subset of patients.
  • Inactivation of Notch3 reduced proliferation and induced apoptosis in chemoresistant ovarian cancer cell lines.

Conclusions:

  • Notch3 expression is associated with chemoresistance and poorer clinical outcomes in advanced ovarian cancer.
  • The Notch3 pathway represents a potential novel therapeutic target for overcoming chemoresistance in ovarian cancer.
  • Targeting Notch3 may offer a new strategy for treating advanced, treatment-resistant ovarian cancer.

More Related Videos

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

Related Concept Videos

Notch Signaling Pathway03:14

Notch Signaling Pathway

The Notch signaling pathway is a major intracellular signaling pathway that is highly conserved over a broad spectrum of metazoan species. It stands unique from other intracellular signaling mechanisms in animals because notch protein itself acts as the receptor as well as the primary signaling molecule.
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not until 1985...
Notch Signaling Pathway03:14

Notch Signaling Pathway

The Notch signaling pathway is a major intracellular signaling pathway that is highly conserved over a broad spectrum of metazoan species. It stands unique from other intracellular signaling mechanisms in animals because notch protein itself acts as the receptor as well as the primary signaling molecule.
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not until 1985...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...